| Sažetak (hrvatski) | Virusi iz herpes grupe (herpes simpleks virus, HSV; varičela-zoster virus, VZV; citomegalovirus, CMV; Epstein-Barrov virus, EBV) su značajan uzrok smrtnosti u imunokompromitiranih osoba. Cilj rada bio je analizirati učestalost HSV-1, HSV-2, VZV, CMV i EBV u bolesnika koji se liječe hemodijalizom. Tijekom trogodišnjeg razdoblja (2013.-2015.) ispitano je ukupno 152 uzastopno pristiglih uzoraka seruma bolesnika na hemodijalizi te 150 uzoraka seruma zdravih osoba (kontrolna skupina) na prisutnost herpes virusnih IgM/IgG protutijela. Serološko testiranje učinjeno je pomoću komercijalnog dijagnostičkog imunoenzimnog testa (ELISA) ili imunoenzimnog testa s fluorescentnom detekcijom (ELFA). Bolesnici na hemodijalizi bili su značajno češće CMV IgG seropozitivni u odnosu na kontrolnu skupinu (88,2% prema 78,7%, p=0,011). Nadalje, seroprevalencija HSV-1 i VZV također je bila viša u bolesnika na hemodijalizi, no statistička značajnost nije dostignuta (85,5% prema 80,0%, p=0,054; 99,3% prema 96,0%, p=0,051). Učestalost HSV-2 i EBV protutijela nije se razlikovala između skupina (12,5% prema 12,7%, p=0,137, odnosno 98,0% prema 95,3%, p=0,113). IgG seroprevalencija nije se razlikovala u odnosu na spol i mjesto prebivališta. Rezultati logističke regresije pokazali su da je starija životna dob značajan čimbenik rizika za CMV i EBV seropozitivnost (porastom dobi za jednu godinu CMV OR=1,055; 95%CI=1,030-1,080; EBV OR=1,075, 95%CI=1,023-1,130). |
| Sažetak (engleski) | Herpes group viruses (herpes simplex virus, HSV; varicella-zoster virus, VZV; cytomegalovirus, CMV; and Epstein-Barr virus, EBV) remain an important cause of morbidity in immunocompromised persons. The aim of the study was to analyze the prevalence of HSV-1, HSV-2, VZV, CMV and EBV in patients undergoing hemodialysis. During a three-year period (2013-2015), 152 consecutive serum samples from hemodialysis patients and 150 healthy subjects (control group) were tested for the presence of IgM/IgG antibodies to herpes group viruses. Serologic tests were performed using a commercial enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunofluorescent assay (ELFA). Hemodialysis patients showed significantly higher CMV IgG seropositivity compared to controls (88.2% vs. 78.7%, p=0.011). In addition, seroprevalence rates of HSV-1 and VZV were higher in hemodialysis patients; however, these differences did not reach statistical significance (85.5% vs. 80.0%, p=0.054 and 99.3% vs. 96.0%, p=0.051, respectively). The prevalence of HSV-2 and EBV was similar in both groups (12.5% vs. 12.7%, p=0.137 and 98.0% vs. 95.3%, p=0.113, respectively). There was no difference in IgG seropositivity according to gender and place of residence. Logistic regression showed that older age was a significant predictor for CMV and EBV IgG seropositivity (increase in age by one year: CMV OR=1.055; 95%CI=1.030-1.080 and EBV OR=1.075, 95%CI=1.023-1.130). |
